Nat Rev Mol Cell Biol. 2025 Jan 27. IF: 81.3The roles of mitochondria in global and local intracellular calcium signalling.www.nature.com/articles/s41580-024-00820-1 Nat Rev Mater. 2025 Jan 27. IF: 79.8Delivering living medicines with biomaterials.www.nature.com/articles/s41578-024-00766-y JAMA. 2025 Jan 27. IF: 63.1Essential Thrombocythemia: A Review.www.jamanetwork.com/journals/jama/fullarticle/2829595 Nat Methods. 2025 Jan 27. IF: 36.1A genome-wide atlas of human cell morphology.www.nature.com/articles/s41592-024-02537-7 J Extracell Vesicles. 2025 Jan;14(1):e70038. IF: 15.5Breast Cancer-Derived Extracellular Vesicles Modulate the Cytoplasmic and Cytoskeletal Dynamics of Blood-Brain Barrier Endothelial Cells.www.onlinelibrary.wiley.com/doi/10.1002/jev2.70038 Annu Rev Med. 2025 Jan;76(1):243-255. IF: 15.1New Oral Selective Estrogen Receptor Degraders Redefine Management of Estrogen Receptor-Positive Breast Cancer.www.annualreviews.org/doi/10.1146/annurev-med-052423-122001 Nat Commun. 2025 Jan 27;16(1):1077. IF: 14.7A compendium of Amplification-Related Gain Of Sensitivity genes in human cancer.www.nature.com/articles/s41467-025-56301-2 Adv Sci (Weinh). 2025 Jan 27. IF: 14.3Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP.www.onlinelibrary.wiley.com/doi/10.1002/advs.202407494 Cell Death Differ. 2025 Jan 27. IF: 13.7Age-dependent differences in breast tumor microenvironment: challenges and opportunities for efficacy studies in preclinical models.www.nature.com/articles/s41418-025-01447-1 Nat Chem Biol. 2025 Jan 27. IF: 12.9Plasma membrane-associated ARAF condensates fuel RAS-related cancer drug resistance.www.nature.com/articles/s41589-024-01826-8 J Adv Res. 2025 Jan 25. IF: 11.4Hypericin photoactivation induces triple-negative breast cancer cells pyroptosis by targeting the ROS/CALR/Caspase-3/GSDME pathway.www.sciencedirect.com/science/article/pii/S2090123225000591 J Adv Res. 2025 Jan 24. IF: 11.4Ailanthone induces triple-negative breast cancer cells death involving the inhibition of OTUB1-mediated ERRalpha deubiquitylation.www.sciencedirect.com/science/article/pii/S2090123225000542 Clin Cancer Res. 2025 Jan 27. IF: 10.0Receptor CDCP1 is a potential target for personalized imaging and treatment of poor outcome HER2+, triple negative and metastatic ER+/HER2- breast cancers.www.aacrjournals.org/clincancerres/article/751284 Clin Cancer Res. 2025 Jan 27. IF: 10.0Impact of Race/Ethnicity on Clinical and Genomic Characteristics, Trial Participation, and Genotype-Matched Therapy among Patients with Metastatic Breast Cancer.www.aacrjournals.org/clincancerres/article/751283 eClinicalMedicine. 2025 Jan 27;80:103065. IF: 9.6Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trial.www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00644-8/fulltext Acta Biomater. 2025 Jan 25. IF: 9.4Facile integration of a binary nano-prodrug with alphaPD-L1 as a translatable technology for potent immunotherapy of TNBC.www.sciencedirect.com/science/article/pii/S1742706125000467 NPJ Vaccines. 2025 Jan 27;10(1):18. IF: 6.9Developing anti-TDE vaccine for sensitizing cancer cells to treatment and metastasis control.www.nature.com/articles/s41541-024-01035-3
